News
Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19
20 May 2021
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment...
Read MoreLaurent Pharmaceuticals Provides Clinical Development Update
8 April 2021
Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 PatientsCompletes...
Read MoreEVENTS
Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 3-6 2024, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022